Anthropic Unveils Claude Science; Trump Drug Plan Snags
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Anthropic released Claude Science, a separate application that optimizes its large language model for scientific laboratories and pharmaceutical research operations.
- Claude Science is the first dedicated interface and product for scientists released by a large AI developer, described by Anthropic as a beachhead in its larger push into biology.
- Anthropic plans to develop drugs of its own alongside the Claude Science tool, positioning the AI firm as a future competitor to its pharma clients.
- President Trump promised to make U.S. prescription drug prices the cheapest in the world, but a closely watched Medicaid pilot program could expose the limits of buy-in among mid-sized and smaller pharmaceutical companies.
- The administration convinced 17 of the largest global drugmakers to offer 'most-favored-nation' pricing comparable to what is paid in other developed countries.
- Mid-size pharma companies account for the development of most new innovative medicines but lack the large medicine portfolios that make it easier for big drugmakers to cut deals.
Why it matters: The 17-company MFN deal Trump struck leaves out mid-sized firms that develop most new innovative medicines, testing the reach of his 'cheapest in the world' promise. Anthropic's Claude Science launch, paired with plans to develop drugs of its own, turns the AI firm into a potential competitor to its pharma lab clients.
